菸鹼醯胺核糖 Nicotinamide Riboside × 胰島素阻抗
The totality of human evidence points to NO benefit of nicotinamide riboside for insulin resistance.
The totality of human evidence points to NO benefit of nicotinamide riboside for insulin resistance. The flagship Dollerup 2018 RCT (n=40, 2000 mg/day, 12 weeks) used the gold-standard hyperinsulinemic-euglycemic clamp and found no improvement in insulin sensitivity, endogenous glucose production, or glucose disposal in obese insulin-resistant men; three further RCTs (the same group's 2019 OGTT/incretin study, a 2020 crossover trial n=13, and a 2025 pediatric-survivor pilot n=20) all corroborate the null result. The strong preclinical signal in obese/diabetic mice did not translate to humans, and no medical society, government agency, or major clinic addresses or endorses NR for this use. Because the best available evidence is consistent in showing the intervention does not work for the outcome (rather than merely being absent), this warrants grade D — evidence against / negligible benefit — not U. The chief limitation is that trials were short and small and none enrolled diagnosed type 2 diabetics, but four consistently null RCTs including a clamp study make a future positive signal unlikely.
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.54
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — | C→D 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
台灣社群（PTT FITNESS/Health/BeautySalon、Dcard、Mobile01、痞客邦）幾乎沒有以「菸鹼醯胺核糖（NR）改善胰島素阻抗」為主題的實測討論。胰島素阻抗相關串集中在飲食、運動與減醣，未提及 NR；抗老 NAD+ 前驅物的討論則幾乎被 NMN 壟斷，NR 多僅在「NMN vs NR 比一比」的比較文中被附帶提及且常被評為次選。此 intervention×condition 配對在台灣社群屬冷門、無可信使用經驗共識，故 not_addressed。
無共識（社群幾無 NR 用於胰島素阻抗之實測心得，討論量不足以歸納）
- 強化生活型態介入（飲食加運動，目標減重 5–7%）
- 中等強度規律運動（每週 150 分鐘）
- Metformin（二甲雙胍）
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-insulin-resistance-INT-nicotinamide-riboside-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "菸鹼醯胺核糖能改善胰島素阻抗",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 1,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🔴 D 反證據"
}
}